RECEIVED

CENTRAL FAX CENTER

MAR 0 8 2004

OFFICIAL

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association 2421 N.W. 41st Street Suite A-1 Gainesville, FL 32606

Telephone (352) 375-8100 Facsimile (352) 372-5800

TO:

Examiner Alana M. Harris

V

Examining Group 1642

FROM: Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

COMPANY:

United States Patent and

Trademark Office

DATE: March 8, 2004

FAX NO.:

703-872-9306

NO. OF PAGES

(INCLUDING COVER SHEET): 2

SUBJECT/MESSAGE:

Re:

U.S. Patent Application Docket No. USF-T136

MUTATED SRC ONCOGENE COMPOSITION AND METHODS Serial No.: 09/444,711; Date filed: November 24, 1999

Applicants: Timothy J. Yeatman, Rosalyn B. Irby

Submission to PTO:

1. Statement of Substance of Interview under 37 C.F.R. §1.133

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

H:\FORMS\FAX\PTO2.DOC/DNB/mv

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and

Trademark Office on March 8, 2004

Glenn P. Ladwig, Patent Attorney

STATEMENT OF SUBSTANCE OF

INTERVIEW

Examining Group 1642

Patent Application

Docket No. USF-T136

Serial No. 09/444,711

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Alana M. Harris

Art Unit

1642

Applicants

Timothy J. Yeatman, Rosalyn B. Irby

Serial No.

09/444,711

Filed

November 24, 1999

Confirm. No.:

9003

For

Mutated SRC Oncogene Composition and Methods

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW UNDER 37 C.F.R. §1,133

The applicants wish to thank Examiner Harris for the courtesy of the telephonic examiner interview conducted on February 17, 2004 with the undersigned. The remarks set forth in the Interview Summary Form that accompanied the Notice of Allowability dated February 23, 2004 are consistent with the substance of that interview and are believed to address the outstanding issues as discussed during the interview. Permission was granted by the undersigned during the interview to amend claims 113, 116, 117, 121, 123, 126, 127, 128, 131, 139, 147, 150, and 151, and to cancel claims 115, 119, 125, 149, and 153. SEQ ID NO: 4 is a truncated form of the c-Src polypeptide. The polynucleotide of claim 114 comprises nucleotides 1 to 1593 of SEQ ID NO:3.

Respectfully submitted

Glenn P. Ladwig Patent Attorney

Registration No. 46,853

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

GPL/niv